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Abstract CD30L is frequently expressed on acute myeloid
leukemia (AML) blasts. Its presence is associated with the co-
expression of interleukin-4 (IL-4) receptor and with the
expansion of specific T-helper 2 (Th2) cell subsets producing
IL-4 and expressing CD30. Recombinant CD30L-bearing cells
up-regulated the expression of surface CD30 and increased the
production of IL-4 and soluble (s) CD30 by co-cultured T cells.
These findings were confirmed with AML blasts expressing
surface CD30L, where blocking anti-CD30 antibodies complete-
ly abolished the release of sCD30 and reduced the production of
IL-4. Our data indicates a direct role of CD30L+ neoplastic cells
in driving the immune response toward a Th2-polarized non-
protective state. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
The tumor necrosis factor (TNF)/TNF receptor superfami-
lies have been shown to play a pivotal role in the regulation of
cellular growth, di¡erentiation and programmed cell death in
several biologic systems, including the immune compartment
[1,2]. In addition to well known members, TNFRs, CD40,
CD30, CD95, OX40, 4-1BB and their respective ligands
[1,2], new related receptors and ligands have been more re-
cently identi¢ed, such as RANK and its speci¢c ligand,
RANKL, and TRAIL with its three related receptors,
TRAIL-R1, 2, 3 [1,2].
We have previously shown that CD30L [3] is frequently
expressed in human hemopoietic malignancies of myeloid ori-
gin, being detectable on tumor cells from about 60% of pa-
tients with acute myeloid leukemia (AML) [4]. Expression of
CD30L on AML blasts is statistically associated with some
unfavorable clinical features, including hyperleukocytosis,
high absolute numbers of circulating blasts and thrombocyto-
penia [4], thus suggesting the involvement of CD30L in deter-
mining a selective enhancement of leukemic blasts growth.
Subsequently, we found [5,6] that leukemic blasts presenting
surface CD30L possess a characteristic cytokine receptor pat-
tern, that makes them ideal targets for T-helper 2 (Th2)-type
cytokines [7^9]. Moreover, CD30L AMLs are associated
with an expansion of speci¢c Th2 cell subsets producing in-
terleukin-4 (IL-4) and expressing the CD30L counter-recep-
tor, CD30 [5,6]. Since IL-4 enhances in vitro proliferation of
CD30L leukemic blasts [5,6], our data indicates that the
selective interaction of CD30 Th2 cells with leukemic pro-
genitors may contribute to the progression of this peculiar
subset of AMLs.
In the present study, we demonstrate the capability of
CD30L to up-regulate expression of surface CD30, release
of soluble (s) CD30 and production of IL-4 in pre-activated
T cells upon co-culture. This data demonstrates a direct role
of CD30L in favoring the expansion of Th2 cell subsets.
2. Materials and methods
2.1. Cell lines and culture conditions
The CD30L-expressing Burkitt lymphoma cell line DG-75 was ob-
tained through the German Collection of Microorganisms and Cell
Cultures (Braunschweig, Germany); the QT6 quail ¢broblast cell line
was kindly provided by G. Man¢oletti (University of Trieste, Italy).
Cell lines were kept in Iscove’s modi¢ed Dulbecco’s medium (Bio-
chrom KG, Germany) supplemented with 20% fetal calf serum (Bio-
chrom KG).
2.2. Monoclonal antibodies (mAbs) and £ow cytometry
Expression of CD3, CD30 and CD30L in transfected QT6 ¢bro-
blasts, resting or activated T cell and AML samples were analyzed by
single or two-color immuno£uorescence methods, essentially as re-
ported [4]. Sources and speci¢cities of mAbs and control immuno-
globulins have been reported in detail previously [4,10]. Viable, anti-
body-labeled cells were identi¢ed according to their forward and side
scatter, electronically gated and assayed for surface £uorescence on a
FACScan £ow cytometer (Becton-Dickinson, Mountain View, CA,
USA).
2.3. RNA isolation and reverse transcriptase-polymerase chain reaction
(RT-PCR)
Total RNA (1 Wg) was extracted by the guanidium thiocyanate
method [11] and reverse-transcribed by avian myeloblastosis virus
RT (Promega Co., Madison, WI, USA), as described [4]. A correct
evaluation of the amount of cDNA was guaranteed by a careful check
of ¢rst-strand synthesis through a competitive PCR for the house-
keeping gene L2-microglobulin [12]. Two microliters of cDNA were
ampli¢ed in a 50-Wl volume of ¢nal reaction mix in a PTC150 thermal
cycler (MJ Research, Watertown, MA, USA) with 25 pmol of primer
pairs speci¢c for CD30 and IL-4. PCR conditions were as follows:
3 min at 94‡C followed by 40 cycles of 45 s at 94‡C, 45 s at 60‡C
(62‡C for CD30), 1.5 min (1.0 for CD30) at 72‡C, and a ¢nal exten-
sion of 5 min at 72‡C. Ten-microliter aliquots of ampli¢ed products
were removed after 30, 35 or 40 cycles, run on 1.5% ethidium bro-
mide-stained agarose gels and separately analyzed under UV light.
2.4. Preparation of QT6/CD30L transfectant
cDNA encoding full-length sequence of CD30L was obtained from
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the DG-75 cell line [14] upon ampli¢cation with the following primer
pairs: a sense primer (5P-CTC GAG AAG CTT ACC ACC ATG
GAC CCA GGG CTG CA-3P) annealing to the start codon of
CD30L and tagged with the HindIII site (sequence underlined), and
an antisense primer (5P-ACC GGT GGA TCC CTA AAG GCC
AAG AGA AAC TGT-3P) recognizing the stop codon of CD30L
and tagged with the BamHI site (sequence underlined). PCR condi-
tions were 3 min at 94‡C followed by 35 cycles of 30 s at 94‡C, 45 s at
57‡C, 1.5 min at 72‡C, and a ¢nal extension of 5 min at 72‡C. The
ampli¢cation product, following electrophoresis in 1.5% agarose gel,
was excised from gel, puri¢ed using Qiaex II resin (Qiagen GmbH,
Hilden, Germany) and cloned in TA-vectors (Invitrogen Corporation,
San Diego, CA, USA) according to the manufacturers’ guidelines.
DNA from the resulting clone was digested with HindIII^BamHI,
puri¢ed and subcloned into a HindIII^BamHI-cut pREP7 (Invitrogen
Corporation, San Diego, CA, USA) plasmid. The resulting expression
vector was employed to transfect QT6 quail ¢broblasts (QT6/CD30L)
by using a blend of non-liposomal lipids as transfection-enhancing
reagent (FuGENE 6, Roche Bioscience, Palo Alto, CA, USA). The
same cells transfected with the vector alone (QT6/pREP7) were pre-
pared and utilized as controls. Expression levels of CD30L were mea-
sured by Northern blotting and/or £ow cytometry. QT6 transfectants
were ¢xed at day 2 post-transfection with 1% paraformaldehyde for
15 min, and utilized for co-culture experiments.
2.5. Northern blotting
Twenty micrograms per lane of total RNA, extracted from trans-
fected QT6 and DG-75 cells, were size-fractionated on 1% agarose
gels containing 6.7% formaldehyde, and subsequently blotted onto
nylon membranes (Boehringer Mannheim, Mannheim, Germany)
[10]. Filters were hybridized as described [10] with 1.0U106 cpm/ml
of random primed-labeled CD30L probe (0.7-kb NotI cDNA frag-
ment containing the entire coding region of human CD30L) [3]. After
washings to a ¢nal stringency of 0.2U standard sodium cytrate and
0.1% SDS at 65‡C, ¢lters were exposed to XAR-5 ¢lms (Eastman
Kodak, Rochester, NY, USA) at 380‡C.
2.6. Co-culture experiments of CD3+ T cells with QT6 transfectants
CD3 T cells (0.5^1.0U106/ml) were puri¢ed from leukapheretic
products of healthy donors by immunomagnetic beads conjugated
with anti-CD3 mAbs [4,10] (Miltenyi Biotec, Italy), and co-cultured
in 35-mm 6-well plates along with paraformaldehyde-¢xed QT6/
CD30L or QT6/pREP7 cells, in the presence of 1% PHA. After 48
h of incubation, T cells were collected and utilized for RNA studies or
for two-color analysis in £ow cytometry. Supernatants were harvested
and utilized for determinations of IL-4 and sCD30 levels by speci¢c
sandwich ELISA (RpD System, Minneapolis, MN, USA, IL-4;
Bender MedSystems Diagnostics GmbH, Wien, Austria, sCD30). To
investigate the involvement of the CD30^CD30L pair in cell^cell in-
teractions, in some cases, co-culture experiments were performed in
the presence of an excess (100 Wg/ml) of blocking anti-CD30 BerH2
mAb [13]. This mAb was chosen because it did not interfere with
ELISA-speci¢c mAbs, as demonstrated by almost superimposable
standard curves for sCD30 ELISA assays (Fig. 1).
2.7. Co-culture experiments of autologous CD3+ T cells with
AML blasts
Blast cells from selected AML cases (three CD30L and two
CD30L3 AMLs), diagnosed according to the French^American^Brit-
ish criteria [14], were puri¢ed by centrifugation on a Ficoll-Hypaque
(Pharmacia, Uppsala, Sweden) gradient, and separated from the au-
tologous T-cell fraction as described above. Immunomagnetically pu-
ri¢ed autologous CD3 T cells were co-cultured as above, together
with autologous paraformaldehyde-¢xed CD30L or CD30L3 AML
blasts, in the presence or in the absence of an excess of blocking anti-
CD30 BerH2 mAb [13].
3. Results
3.1. Expression of CD30L by QT6 transfectants
Levels of recombinant CD30L in QT6/CD30L cells, as de-
tected by £ow cytometry (Fig. 2A) and Northern blot analysis
(Fig. 2B), were fully comparable to those expressed by the
CD30L cell line DG-75 [4]. Conversely, no expression of
CD30L was found in QT6 cells transfected with the empty
vector (QT6/pREP7) (Fig. 2A,B).
3.2. Recombinant CD30L up-regulates the expression of CD30
and IL-4 transcripts by T cells
To evaluate a direct role of CD30L in the development of
Th2 cell subsets, paraformaldehyde-¢xed QT6/pREP7 or
QT6/CD30L cells were co-cultured for 48 h with puri¢ed T
cells from healthy donors in the presence or in the absence of
1% PHA. As shown in Fig. 3, recombinant CD30L was able
to modulate the expression of CD30- and IL-4-speci¢c tran-
scripts, as assessed by semi-quantitative RT-PCR. In this re-
gard, while in unstimulated T cells CD30-speci¢c mRNA was
detectable only following 40 ampli¢cation rounds (lane 1),
activation of PBMC by PHA yielded a signi¢cant increase
of CD30 transcripts. In particular, CD30-speci¢c ampli¢ed
products became clearly detectable after 35 cycles in samples
deriving from activated T cells co-cultured with QT6/pREP7
rounds (lane 2), or as low as 30 cycles when QT6/CD30L cells
were employed (lane 4). A similar behavior was observed
when the modulation of IL-4-speci¢c transcripts was investi-
gated (Fig. 3, lanes 5^8). Again, the highest levels of IL-4
mRNA were seen when PHA-activated T cells were co-cul-
tured with CD30L-expressing QT6 cells (Fig. 3, lane 8).
3.3. Recombinant CD30L up-regulates the expression of
surface CD30 protein by pre-activated T cells
The up-regulation of the expression of CD30 in activated T
cells co-cultured with CD30L-bearing cells was con¢rmed at a
protein level. As shown in Fig. 4, a 48-h co-culture of PHA-
activated T cells with QT6/CD30L cells resulted in the up-
regulation of surface CD30 (37% of double-stained cells), as
compared to the same cells co-cultured in the presence of QT6
cells (QT6/pREP7) transfected with the empty vector (16% of
double-stained cells). Conversely, no expression of surface
CD30 was observed on CD3 T cells co-cultured with QT6
cells in the absence of PHA (data not shown).
3.4. Recombinant CD30L up-regulates the production of
sCD30 and IL-4 in supernatants from CD3+ T cells
In a third series of experiments, supernatants from 48-h co-
cultures were collected and analyzed for IL-4 and sCD30 pro-
Fig. 1. Standard curves for sCD30 ELISA assays. Recombinant
sCD30, provided by the manufacturer (Bender MedSystems Diag-
nostics), was diluted in serial two-fold steps starting from a concen-
tration of 25 U/ml. Optical density (O.D.) values were obtained by
reading absorbances on a spectrophotometer at a wavelength of 450
nm. Closed and open squares refer to curves carried out in the ab-
sence or in the presence of an excess (100 Wg/ml) of the anti-CD30
mAb BerH2, respectively. Each experimental point represents the
mean þ S.E.M. of triplicate measurements.
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duction (Fig. 5). No modulation was observed in the absence
of PHA (Fig. 5). In supernatants deriving from PHA-treated
co-cultures, a slight increase in the concentration of both
sCD30 and IL-4 was observed. However, co-cultures of acti-
vated T cells with CD30L-transfected QT6 cells produced the
highest levels of sCD30 (7.21 þ 1.66 U/106 T cells) and IL-4
(51.75 þ 15.5 pg/106 T cells), as compared to supernatants de-
riving from co-cultures of activated T cells and QT6 cells
transfected with an empty vector (sCD30 = 2.1 þ 1.28 U/106
T cells; IL-4 = 10.5 þ 2.9 pg/106 T cells). By blocking CD30/
CD30L interactions by means of the anti-CD30 mAb BerH2,
a striking down-regulation of both sCD30 (2.7 þ 0.8 U/106 T
cells) and IL-4 (23.5 þ 7.0 pg/106 T cells) was observed in
supernatants from co-cultures of QT6/CD30L and activated
T cells (Fig. 5).
3.5. CD30L+ AML blasts up-regulate the production of sCD30
and IL-4 in supernatants from autologous CD3+ T cells
The production of sCD30 and IL-4 in supernatants derived
from co-cultures of autologous pre-activated CD3 T cells
with blast cells isolated from primary AMLs either positive
(Fig. 6A) or negative for surface CD30L [5,6] was investi-
gated. In agreement with data obtained with recombinant
CD30L, a strong increase of both sCD30 (range: 15.4^25.0
U/106 T cells) and IL-4 (range: 79.7^98.6 pg/106 T cells) was
documented in supernatants from co-cultures of PHA-treated
autologous T cells and paraformaldehyde-¢xed blasts from
three cases of CD30L monoblastic leukemia, but not from
two CD30L3 AML cases (Fig. 6B). Again, addition to the
Fig. 2. Expression of recombinant CD30L by QT6 transfectants. A:
Surface expression of CD30L on QT6 cells transfected with the vec-
tor alone (QT6/pREP7, upper panel), or containing the human full-
length CD30L cDNA (QT6/CD30L, intermediate panel) and the
CD30L DG-75 cell line (DG-75, lower panel), as detected in £ow
cytometry by anti-CD30L mAbs (thick lines). Background £uores-
cence (thin lines) was determined by staining cells with an irrelevant
isotype-matched (IgG2b) control mAb. B: Expression of CD30L
gene in the same cells as above. A band corresponding to the entire
open reading frame of the CD30L cDNA (726 bp) was documented
in QT6/CD30L but not in QT6/pREP7 cells, while in the control
cell line DG-75, a single speci¢c transcript of about 3.0 kb, was ob-
served.
Fig. 3. Recombinant CD30L up-regulates the expression of CD30
and IL-4 mRNAs by puri¢ed CD3 T cells. Expression of CD30
(lanes 1^4) and IL-4 (lanes 5^8) mRNAs by CD3 T cells of
healthy donors following co-culture with QT6/pREP7 or QT6/
CD30L cells. T cells were co-cultured with paraformaldehyde-¢xed
QT6/pREP7 or QT6/CD30L cells, in the presence or in the absence
of 1% PHA for 48 h of incubation. Ampli¢cations were carried out
as in Section 2.3.
Fig. 4. Recombinant CD30L up-regulates the expression of surface
CD30 protein by puri¢ed CD3 T cells. Two-color immuno£uores-
cence showing the simultaneous expression of CD3 and CD30 on T
cells co-cultured for 48 h with paraformaldehyde-¢xed QT6/pREP7
or QT6/CD30L cells, in the presence of 1% PHA. Cells were stained
by the anti-CD30 mAb BerH2 (y-axes, red £uorescence) and by
anti-CD3 (x-axes, green £uorescence).
Fig. 5. Recombinant CD30L up-regulates the production of sCD30
and IL-4 by puri¢ed CD3 T cells. Detection of soluble sCD30 and
IL-4 in supernatants of 48-h-old co-cultures by speci¢c ELISA as-
says. CD3 T cells from healthy donors were co-cultured with para-
formaldehyde-¢xed QT6/pREP7 or QT6/CD30L, in the presence or
in the absence of 1% PHA for 48 h of incubation. In some cases,
co-cultures of QT6/CD30L and activated T cells were carried out in
the presence of an excess (100 Wg/ml) of the blocking anti-CD30
mAb BerH2 (QT6/CD30L+PHA+BerH2).
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cultures of an excess of the blocking anti-CD30 BerH2 mAb
[13] completely abolished the release of sCD30 (range: 1.8^4.1
U/106 T cells) and reduced the production of IL-4 (range:
27.0^45.9 pg/106 T cells) at about 50% (Fig. 6B).
4. Discussion
Leukemic blasts presenting surface CD30L [4] display a
characteristic cytokine receptors pattern, including the exclu-
sive expression of IL-4R in the absence of its cognate cyto-
kine, that makes them ideal targets for those cytokines usually
produced by Th2-type cell subsets [5,6]. Furthermore, the ex-
pression of the Th2-associated markers CD30, IL-4 and
GATA-3 [7^9,15] was detected in residual T cells derived
from CD30L AMLs, but not from CD30L3 AMLs [5,6].
Within the spectrum of hematological malignancies, a Th2-
dominated phenotype by residual normal T cells has been
recently reported in B-cell precursor acute lymphoblastic leu-
kemia [16,17]. The expansion of T-cell clones expressing sur-
face CD30, but producing both IL-4 and interferon-Q, was
described also in the residual non-B-cell compartment of B-
cell chronic lymphocytic leukemia (B-CLL) [18]. Interestingly,
CD30L is expressed, although at di¡erent levels, in acute leu-
kemias of lymphoid and myeloid origin, as well as in B-CLL
[4^6]. Since the development of a polarized T-cell response
largely depends on the characteristics of the antigen present-
ing cells [7^9,15], it is conceivable that the expression of
CD30L on neoplastic cells may contribute to determine the
skewing of the immune response toward a Th2 phenotype. In
fact, transfectants expressing recombinant CD30L at a high
surface density, comparable to that expressed by DG-75 cells
[4] or found in CD30Lhigh AMLs [4^6], were able to drive the
di¡erentiation of puri¢ed CD3 T lymphocytes toward a Th2
phenotype. Consistent results were obtained in experiments
carried out with ¢xed AML blasts expressing surface
CD30L. The speci¢city of these ¢ndings were con¢rmed by
the observation that addition of neutralizing anti-CD30 mAb
[13] completely abolished the release of sCD30 and signi¢-
cantly reduced the production of IL-4.
Experiments with QT6 transfectants and autologous AML
blasts, however, suggest that the expression of CD30L,
although necessary, is not su⁄cient to determine a Th2 polar-
ization. In fact, the presence of a T-cell mitogenic factor was
required to attain a signi¢cant up-regulation of CD30 on
CD3 T cells or to increase the release of sCD30 and IL-4.
A number of soluble and/or membrane-bound factors, includ-
ing IL-6, MCP-1 and CD86/B7-2, have been proposed to in-
£uence T-cell subsets commitment speci¢cally tilting their de-
velopment toward a Th2 phenotype [19]. Interestingly, MCP-1
is expressed, as CD30L [4], mainly by monocytic-oriented
leukemic cells [20], CD86/B7-2 has been described on the sur-
face of blast cells in almost one-third of AML cases [21], and
CD40 triggering on CD30L AMLs results in an increased
production of endogenous cytokines, including IL-6 [22]. A
model could be therefore depicted in which blast cell-derived
cytokines (e.g. IL-6 or MCP-1) along with engagement of
surface co-stimulatory molecules, such as CD86/B7-2, may
contribute to the initial priming of T cells toward a Th2 phe-
notype, including expression of CD30. The polarized Th2 re-
sponse could then be ampli¢ed and maintained through spe-
ci¢c interactions of CD30 T cells with CD30L molecules
expressed on AML blasts.
The selective production of IL-4 by CD30 T-cells may
contribute to determine the proliferative and phenotypic fea-
tures of IL-4R/CD30L AMLs. In agreement with this line
of reasoning, exogenous IL-4 is able to enhance the prolifer-
ation of myeloid leukemic blasts [6,23] and to modulate the
membrane expression of some adhesion structures, such as L2
integrins and CD54 (D. Aldinucci et al., unpublished data),
whose presence is signi¢cantly associated with the expression
of CD30L on leukemic cells [4].
Current paradigms indicate that AML cells evade the im-
mune response mainly by lacking essential co-stimulatory sig-
nals for T-cell activation [24,25]. Data presented here implies
that CD30L neoplastic cells may have a direct role in driving
the immune response toward a non-protective state, including
a Th2 polarization. A better understanding of the mechanisms
by which leukemic cells are able to drive the immune system
may eventually lead to alternative therapeutic approaches
aimed to favor the development of a protective anti-leukemic
response.
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